LEXX

Kelowna, British Columbia – September 4 , 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 th through September 16 th , 2026 in New York City.   Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The presentation will be available to view online using this link .

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate   Kelowna, British Columbia – September 1 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office.  The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK") bioanalysis testing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2, the "Study"). The Study examined oral delivery of 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs, amycretin and retatrutide, in a total of 18 different study arms in dogs following formulation and processing using Lexaria's patented DehydraTECHTM ("DHT") drug delivery enabling platform technology formulated in oral tablet and capsule formats.

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.

Kelowna, British Columbia – TheNewswire - July 30, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026 (the “ Reverse Split ”).   The primary goal of the Reverse Split is to increase the per Share market price of the Company's Shares with the objective of regaining compliance with the NASDAQ Capital Market's (“ Nasdaq ”) minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Price Rule ”). The Reverse Split is also being performed in an effort to stabilize uncertain stock conditions in the face of a number of critical business drivers which we believe to be in the best immediate and long-term interests of our shareholders.

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO International Convention ("BIO") in San Diego, CA. "Lexaria had a full schedule at BIO, meeting with a diverse group of companies ranging from innovative smaller tech-focused firms to multi-billion-dollar global pharmaceutical companies," said Richard Christopher, CEO of Lexaria Bioscience Corp. "We are balancing new exploratory corporate opportunities with existing corporate relationships, with the intent of entering into partnership arrangements.

Kelowna, British Columbia – June 25, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14 th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo Nordisk's® (“Novo”) commercially available Wegovy® tablets, over a 5-week duration (the “Study”).   Lexaria is seeking to preserve the superior safety and tolerability profiles evidenced in its previous glucagon-like peptide-1 (“GLP-1”) studies such as Human Study #4 (GLP-1-H24-4 ), combined with pharmacokinetic (“PK”) performance that matches or exceeds the Wegovy® tablet control.  Previous Lexaria salcaprozate sodium (“SNAC”)-inclusive DHT-sema single dose studies such as Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2 ) evidenced PK performance that matched or exceeded the Rybelsus® control arm and also evidenced noteworthy safety and tolerability profiles.

Potentially valuable novel compositions being investigated Lexaria also receives additional new granted patent

More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update. On June 7th, Novo Nordisk® ("Novo") announced that over three million Wegovy® pill prescriptions had been filled since its initial launch on January 5, 2026, in what they call "one of the strongest US pharmaceutical launches by volume on record".

More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as treatable with GLP-1 drugs